• Question: Would the coadministration of liposomal adjuvants enhance the nerve block duration of liposomal bupivacaine? • Findings: Coinjection of liposomal bupivacaine with liposomal dexamethasone phosphate and liposomal dexmedetomidine prolonged the duration of sciatic nerve block 2.9-fold compared to liposomal bupivacaine alone.
• Meaning: Duration of nerve block from liposomal bupivacaine could be enhanced by the addition of encapsulated adjuvants and potentially improve patient care.
C urrent pain treatments rely to a great degree on orally administered opioids. 1 However, due to their limited effectiveness and significant side effects, alternative methods of pain control are of interest, 2,3 such as local anesthesia. Bupivacaine (Bup) is a local anesthetic frequently utilized clinically in infiltration, regional, and neuraxial blockade. Its use for postoperative pain-in the absence of delivery by a catheter-has been limited by its relatively brief duration of action. 4, 5 Placement and maintenance of such catheters, while necessary to achieve prolonged pain control, require specialized skilled personnel and an inpatient setting. Furthermore, the patient must be tethered to an external delivery system, presenting a potential portal for infection.
Previous studies have combined local anesthetics with adjuvants such as the α 2 -adrenergic agonist dexmedetomidine (DMED) to extend the duration of the nerve block while also reducing local inflammation. 6 DMED could prolong the duration of nerve block though vasoconstriction, 7 by maintaining the local concentration of the local anesthetic, or by inhibition of the hyperpolarization-activated cation current (I h current). 8 The glucocorticoid agonist dexamethasone (Dex) has also been used to prolonged nerve block from local anesthetics. 9 Possible mechanisms by which Dex could prolong nerve block with local anesthetic solutions include BACKGROUND: The relatively short duration of effect of local anesthetics has been addressed by encapsulation in drug delivery systems. Codelivery with a single compound that produces an adjuvant effect on nerve block but without intrinsic local anesthetic properties can further prolong the nerve block effect. Here, we investigated whether codelivery of more than 1 encapsulated adjuvant compound can further enhance nerve blockade. METHODS: Liposomes loaded with bupivacaine (Bup), dexamethasone phosphate (DexP), or dexmedetomidine (DMED) were synthesized and its in vitro drug release profiles were determined. Animals (Sprague-Dawley rats) were injected with liposomal Bup (Lipo-Bup) and adjuvants at the sciatic nerve and underwent a modified hot plate test to assess the degree of nerve block. The duration of block was monitored and the tissue reaction was assessed. RESULTS: Coinjection of Lipo-Bup with liposomal DexP (Lipo-DexP) and liposomal DMED (Lipo-DMED) prolonged the duration of sciatic nerve block 2.9-fold compared to Lipo-Bup alone (95% confidence interval, 1.9-to 3.9-fold). The duration of the block using this combination was significantly increased to 16.2 ± 3.5 hours compared to Lipo-Bup with a single liposomal adjuvant (8.7 ± 2.4 hours with Lipo-DMED, P = .006 and 9.9 ± 5.9 hours with Lipo-DexP , P = .008). The coinjection of Lipo-Bup with liposomal adjuvants decreased tissue inflammation (P = .014) but did not have a significant effect on myotoxicity when compared to Lipo-Bup alone. Coinjection of Lipo-Bup with unencapsulated adjuvants prolonged the duration of nerve block as well (25.0 ± 6.3 hours; P < .001) however was accompanied by systemic side effects. CONCLUSIONS: Codelivery of Lipo-DexP and Lipo-DMED enhanced the efficacy of Lipo-Bup. This benefit was also seen with codelivery of both adjuvant molecules in the unencapsulated state, but with marked systemic toxicity. (Anesth Analg 2018;126:1170-5)
Prolonged Duration Local Anesthesia Using Liposomal Bupivacaine Combined With Liposomal Dexamethasone and Dexmedetomidine vasoconstriction, 10 antiinflammatory effects, 11 and the activation of inhibitory potassium channels on C fibers. 12 However, these drugs tend to have a relatively modest effect on the duration of nerve block from local anesthetic solutions. 6, 13 A wide variety of controlled release systems have been studied to further prolong the duration of local anestheticinduced nerve block.
14 Such systems allow the drug concentration near the nerve to be maintained at therapeutic levels for a prolonged period while minimizing systemic absorption. Liposomes, because of their biocompatibility 15 and adoption into clinical practice, have been utilized to encapsulate Bup to provide prolonged duration of local anesthesia. 16 Encapsulating local anesthetics together with adjuvant molecules can markedly prolong the duration of effect. For example, while Bup microspheres injected at the sciatic nerve produce nerve block lasting a number of hours, coencapsulation with Dex resulted in nerve block lasting days. 17 Similarly, rat sciatic nerve block from microspheres containing 2 local anesthetics (Bup and the site 1 sodium channel blocker tetrodotoxin) was greatly enhanced by addition of Dex (from 1.5 to >9 days). In these examples, the effect of drug delivery systems containing 1 or more local anesthetics was enhanced by coencapsulation with a single adjuvant compound with no intrinsic local anesthetic activity.
Here, we investigated whether codelivery of more than 1 adjuvant molecule without intrinsic local anesthetic activity can enhance the duration of block from encapsulated local anesthetics. We used Bup as the local anesthetic, and DMED and dexamethasone phosphate (DexP) as the 2 adjuvants. Sprague-Dawley rats were used as the animal model, consistent with studies in the field, 18, 19 to enable us to investigate the effect of drug combinations with all other parameters kept constant.
METHODS

Liposome Preparation and Characterization
Liposomes were prepared by the thin film hydration method. [20] [21] [22] A lipid mixture of 1,2-distearoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids, Alabaster, AL) and cholesterol (Sigma, St. Louis, MO) 2:1 molar ratio was dissolved in a 9:1 chloroform:methanol solution. The lipid mixture underwent vacuum evaporation to form a dry lipid film. T-butanol was used to dissolve the lipid thin film and freeze-dried to form a lipid cake. The lipid cake was hydrated with phosphate buffered saline (PBS), DMED solution (1 mg/mL PBS; Sigma), DexP solution (50 mg/mL PBS; Sigma), or 250 mM (NH 4 ) 2 SO 4 . The liposomes then underwent 10 freeze-thaw cycles followed by dialysis against PBS for 48 hours. Bup (Sigma) was loaded into liposomes using a previously reported remote loading technique. 23 Briefly, after dialysis in PBS, the liposomes that were hydrated with 250 mM (NH 4 ) 2 SO 4 were loaded with Bup on incubation with a 50 mg/mL Bup hydrochloride solution at 50°C for 1 hour. The liposomes were then dialyzed against PBS for 48 hours.
Liposome size was determined by dynamic light scattering (Delsa Nano; Beckman Coulter, Brea, CA). Drug loading was determined by high-performance liquid chromatography after disrupting the liposomes with 100 mM octyl β-D-glucopyranoside (Sigma).
In Vitro Drug Release Kinetics
Drug release kinetics were performed by dialyzing 100 µL of liposome solution against 14 mL of PBS at 37°C in a Slide-ALyzer MINI dialysis device (Thermo Fisher, Waltham, MA) with a 20-kDa molecular weight cut-off. Samples were collected at predetermined time intervals and replaced with fresh PBS. The concentration of drug in each sample was determined by high-performance liquid chromatography ( Figure 1 ).
Animal Studies
Animal studies were performed with protocol approved by the Boston Children's Hospital Animal Care and Use Committee that conform to the requirements of the International Association for the Study of Pain. 24 Starting at 6 am, the rats were in light for 12 hours of each day. Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 320-425 g were used for this study.
The rats were randomly allocated to each experimental group and anesthetized with isoflurane-oxygen followed by injections of test materials at the sciatic nerve. 21 The liposomal drug combinations were: 300 µL liposomal bupivacaine (Lipo-Bup) with 100 µL liposomal DMED (Lipo-DMED) and/or 100 µL liposomal DexP (Lipo-DexP). We also injected the rats with a mixture of 300 µL of PBSfilled liposomes (Lipo-PBS) with 100 µL Lipo-DMED or 100 µL Lipo-DexP to serve as controls. The free solution drug combinations provided equal mass of drug as the liposomal solution: 300 µL of 15 mg/mL Bup hydrochloride (in citrate buffer) with 100 µL of 0.4 mg/mL DMED solution and/or 100 µL of 2.5 mg/mL DexP solution. The duration of sensory nerve blocks were measured at predetermined time intervals using a modified hot plate test. 18, 19 In brief, the rat's hindpaw was placed on a hot plate at 56°C, and the degree of nerve block was determined by measuring the time until the animal removed its hindpaw from the hot plate. Two seconds was normal latency and indicative of no sensory nerve blockade. Twelve seconds was the maximum amount of time the hindpaw was kept on the hot plate before being removed to prevent thermal injury. Duration of effective block was defined as the duration required for the thermal latency to return to 7 seconds, which was the midpoint between the maximum block (12 seconds) and baseline (2 seconds). The duration of local anesthesia from that successful block was calculated as the time for the latency to return to 7 seconds. 22 The number of animals in each group was as follows: Lipo-Bup + Lipo-DMED, n = 5; Lipo-Bup + Lipo-DexP, n = 8; Lipo-Bup + Lipo-DexP + Lipo-DMED, n = 10; and N = 4 for all other groups.
Histology
Four days after the injections of liposomes, the animals were euthanized with carbon dioxide. Tissue samples containing the sciatic nerve and adjacent muscle were collected and underwent standard hematoxylin and eosin (H&E) staining procedures. The H&E slides were scored for myotoxicity (0-6) and for inflammation (0-4) as previously reported. 22, 25 These scores were assigned by a researcher blinded to the status of each sample (A.Y.R.). Inflammation was scored subjectively to quantify severity; 0 was normal and 4 was severe inflammation. Myotoxicity was evaluated by the nuclear internalization and regeneration of myocytes, 2 representative characteristics of myotoxicity in local anesthesia. The scoring scale was as follows: 0 = normal; 1 = perifascicular internalization; 2 = deep internalization (>5 cell layers); 3 = perifascicular regeneration; 4 = deep tissue regeneration (>5 cell layers); 5 = hemifascicular regeneration; 6 = holofascicular regeneration.
Statistical Analysis
Myotoxicity and inflammation histological scores were analyzed by the nonparametric Mann-Whitney U test due to their ordinal scales and reported as median scores and ranges for liposomal combinations compared to Lipo-Bup alone with a Bonferroni adjusted P < .017 to account for 3 planned comparisons (the significance criterion was set as 0.05/M to maintain α of .05 for each outcome, where M is the number of tests within each hypothesis). Duration of sciatic block was compared using 1-factor analysis of variance (ANOVA) with Dunnett post hoc tests. 25 Fieller theorem was used to construct a 95% confidence interval (CI) around the fold difference of prolonged nerve block between coinjection of Lipo-Bup with Lipo-DMED and Lipo-DexP as compared to Lipo-Bup. 26 Effect sizes regarding mean differences in block duration relative to Lipo-Bup + Lipo-DMED + Lipo_DexP were determined by ANOVA and shown graphically with 95% CIs. In this study, detection of large mean differences or effects (4-5 hours) in nerve block duration would be considered scientifically meaningful. The sample sizes used for groups for in vivo nerve block experiment (Figure 3 ) provided 80% power to detect effect sizes of 1.25 or larger, based on a noncentral F statistic in ANOVA (G*Power, Düsseldorf, Germany). Statistical analysis was performed using Stata software Release 15 (Stata Statistical Software; StataCorp LLC, College Station, TX).
RESULTS
Liposomal Properties
Drug-loaded liposomes ranged in diameter between 2 and 5 µm (Table 1) as measured by dynamic light scattering. The average Bup, DMED, and DexP concentrations of the liposomal solutions were 14.7, 0.38, and 2.5 mg/mL, respectively (Table 1 ). All liposomal solutions had an average lipid concentration of 62.5 mg/mL.
In Vitro Drug Release
Liposomal drug release profiles were measured by dialyzing 100 µL of liposomal samples against 14 mL of PBS, with changes in solution at predetermined time-points, at which the drug content was measured (Figure 1 ). Liposomal Bup (Lipo-Bup) showed relatively rapid release of Bup in the first 48 hours followed by slower release ( Figure 1) ; 39% of drug was released by the end of the release experiment (144 hours). With liposomal DMED (Lipo-DMED), the release rate of DMED was relatively constant throughout the 6 days, releasing 81% of drug in that time frame. Liposomal DexP (Lipo-DexP) showed rapid release of DexP within the initial 12 hours followed by a slower drug release rate; 46% of drug was released in 6 days. The free, unencapsulated drugs were all released from the dialysis kits very quickly in the same experimental set-up, demonstrating the controlled release of each drug from its respective liposomal formulation. 
Duration of Sciatic Nerve Blockade
Under oxygen-isoflurane anesthesia, animals were injected at the sciatic nerve with a combination of liposomal solutions including 300 µL Lipo-Bup, with or without 100 µL Lipo-DMED, and/or 100 µL Lipo-DexP, and/or 100-200 µL blank (no drug) liposomes (Lipo). On awakening, animals underwent neurobehavioral testing (modified hot plate test; see Methods). Lipo-DMED or Lipo-DexP with Lipo-PBS did not result in nerve block. These results also implied that free DMED and DexP did not have intrinsic peripheral nerve blocking activity, consistent with previous reports.
13,26
Injection of Lipo-Bup induced a sensory nerve blockade of 5.5 ± 0.7 hours (mean ± standard deviation; Figure 2 ). An equal volume and concentration of free Bup induced a nerve block duration of 3.6 ± 1.2 hours (P = .03 in comparison with Lipo-Bup; Figure 2 ). Coinjection of free Bup with DMED and DexP did not result in a longer duration of block than from free Bup alone (Figure 2) . Coinjection of LipoBup, Lipo-DMED, and Lipo-DexP (Lipo-Bup + Lipo-DMED + Lipo-DexP) prolonged sensory nerve blockade 2.9-fold to 16.2 ± 3.5 hours (Figure 3 , P < .01 compared to Lipo-Bup; the 95% CI for the fold difference between the durations of nerve block for Lipo-Bup and for Lipo-Bup + Lipo-DMED + Lipo-DexP was determined by Fieller theorem to have a lower bound of 1.9 and upper bound of 3.9), significantly longer than block from coinjection of Lipo-Bup with Lipo-DMED (Lipo-Bup + Lipo-DMED) or Lipo-DexP (Lipo-Bup + Lipo-DexP) that resulted in nerve block durations of 8.7 ± 2.4 and 9.9 ± 5.9 hours, respectively (Figure 3 ; P < .01). No contralateral nerve block was observed in any of the groups, suggesting a lack of systemic drug distribution or toxicity.
To determine whether the enhancement of block from Lipo-Bup required that the adjuvant drug be encapsulated, we injected Lipo-Bup with free DexP and DMED, at the same final concentrations as with their liposomal formulations (see Methods). The resulting nerve block lasted 25.0 ± 2.6 hours (Figure 3) . However, animals appeared to be heavily sedated in the first 4 hours postinjection, with little activity.
Histology
The sciatic nerve and adjacent muscle tissues were harvested 4 days after injection. Macroscopic examination showed a white material (the liposomes) surrounding the nerve (Figure 4) . Tissue samples were made into H&E-stained slides and scored for myotoxicity (0-6) and inflammation (0-4) ( Table 2 and Supplemental Digital Content, Figure S1 , http://links.lww.com/AA/C157; see Methods for details). Lipo-Bup, Lipo-Bup + Lipo-DexP, and Lipo-Bup + Lipo-DMED produced comparable degrees of inflammation, with observable inflammatory infiltrate that consisted of lymphocytes and neutrophils in the soft tissues surrounding the muscle layer (Table 2 and Supplemental Digital Content, Figure S1 , http://links.lww.com/AA/C157). The inflammatory infiltrate was also present in the perifascicular layers of the muscle tissue (Table 2 and Supplemental Digital Content, Figure S1 , http://links.lww.com/AA/C157). Lipo-Bup + Lipo-DMED + Lipo-DexP had a statistically significantly reduced inflammation score compared to Lipo-Bup, with similar cell types (P = .014, Figure 4) . Foamy macrophages were observed in all groups, suggesting the ingestion of liposomes. The myotoxicity score for Lipo-Bup + Lipo-DMED + Lipo-DexP was similar to that of Lipo-Bup (P = .19), consisting of myocytes of nuclear internalization throughout the muscle tissue and occasionally showing myocyte regeneration.
DISCUSSION
Codelivery of 2 adjuvant drugs increased the duration of effect of Lipo-Bup almost 3-fold. The adjuvant molecules used here work by distinct but partially overlapping mechanisms. One possibility is that the activation of C-fiber glucocorticoid receptors 12 by DexP may block nerve signal transduction and be combined with the vasoconstriction effect of DMED 6, 27 mediated by the α 2 -adrenergic receptor, 7, 26 or DMED's direct action on the peripheral nerve, where the inhibition of the hyperpolarization-activated cation current (I h current) blocks pain signal transduction, 8 to produce such prolongation effects. The exact mechanism remains to be studied. These results cannot allow us to assert that the effect of the 2 adjuvants are synergistic versus additive, ie, that a similar effect might not have been achieve by simply increasing the dosage of DexP or DMED. However, it is important to be aware that both adjuvant molecules can have potential side effects with increasing dose. This is clearly seen, for example, in the case of DMED, where excessive dosing can lead to systemic sedation. 28 The use of 2 adjuvants that have a common desired effect (enhancement of nerve blockade) but different toxicities could allow for longer blocks to be achieved safely. It also bears mentioning that the ability of adjuvant molecules to prolong nerve block does have a ceiling. For example, Dex does not prolong the duration of nerve block from Bup in polymeric microspheres beyond a w/w loading of 0.05%. 17 Codelivery of adjuvants that act by different mechanisms could potentially help increase the peak effect.
Coinjection of the 3 drugs in free form did not significantly prolong the duration of block over that of free Bup, while coinjection of encapsulated forms did. This discrepancy between the effects of Dex on free and encapsulated local anesthetics is consistent with previous reports with the rat sciatic nerve model. 13, 17 DMED has been reported to cause a modest (2.5-4 hours) prolongation of nerve block in rats 6 ; it may be that we did not see that effect here because we used a larger dose of Bup, resulting in a longer duration of nerve block of 3.6 hours.
Unencapsulated, free DMED and DexP were able to prolong the effect of Lipo-Bup. Previous studies on the effects of vasoconstrictors such as DMED 26 and epinephrine 29 on local anesthetics suggest that vasoconstriction at the sciatic nerve lasts approximately 3 hours. While such relatively brief periods of vasoconstriction can greatly enhance the duration of nerve block from compounds such as tetrodotoxin, which have difficulty penetrating into nerves due to their hydrophilicity, they tend to have a modest effect on the duration of amphiphilic drugs such as Bup. 18 The mechanism by which the free adjuvants prolonged the duration of block of Lipo-Bup is not known to us. We postulate, however, that the relatively brief effects of free adjuvants would not be able to produce the multiday nerve blocks that have been achieved with some formulations. 17, 20, 30 Coinjection of Lipo-Bup with unencapsulated DMED and DexP provided a longer nerve block than its coinjection with encapsulated DMED and DexP. This unexpected effect may be due to the fact that the encapsulated drugs (DMED and DexP) were released at a much slower rate than the free drug initially (Figure 1) , and the rate of release of the encapsulated drugs decreased further over time. Thus, while the given dose of the encapsulated drugs may been released for over a longer period than the free compounds, their release above a therapeutic threshold for effectiveness may have been shorter.
Lipo-Bup induced mild to moderate myotoxicity, consistent with previous reports 4, 16 ; it would be expected to resolve fully with time. 16, 31 Such myotoxicity has not caused major clinical concerns, and liposomal bupivacaine has been commercialized. 32 The coinjection with Lipo-DMED and LipoDexP did not cause further tissue injury and was able to prolong the nerve block by approximately 3-fold. Moreover, all of the drugs and lipid material used in this study are Food and Drug Administration-approved for use in humans.
Further studies are needed to investigate the mechanisms by which DexP and DMED prolong block Lipo-Bup. Also, throughout this study, a single concentration was used for each adjuvant to demonstrate proof-of-concept of the effect on the coinjection of 2 encapsulated and unencapsulated adjuvants with Lipo-Bup. A more detailed study of the effects of various dosages is needed to minimize side effects and maximize the duration of prolonged nerve block from Lipo-Bup, as well as to establish whether the effects of Data are median scores with the range in parentheses. Liposomal combination groups were compared to Lipo-Bup alone using the nonparametric MannWhitney U test, resulting in 3 planned comparisons (see Methods). Abbreviations: Lipo-Bup, liposomal bupivacaine; Lipo-DexP , liposomal dexamethasone phosphate; Lipo-DMED, liposomal dexmedetomidine. a P = .016. b P = .014.
